|
Carcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
MGMT promoter methylation progressively increased from carcinoids to high-grade carcinomas.
|
31280263 |
2020 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Hierarchical clustering isolated three relevant clusters: (i) cluster of microsatellite stable mucinous adenocarcinomas (54%) with KRAS mutation, and frequent MGMT changes, more frequently located in the left colon, often associated with contiguous precursor adenoma; (ii) cluster of BRAF-mutated mucinous adenocarcinomas (28%) with either microsatellite instability-high or microsatellite stable status, occurring in elderly female patients, nearly all located in the right colon, having the signature of serrated pathway of carcinomas; and (iii) a heterogeneous cluster of microsatellite instability-high mucinous carcinomas (18%), including inherited colorectal carcinomas, displaying a high-grade histological pattern.
|
28429715 |
2017 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We studied DNA methylation of CpG islands of the MGMT gene and its relation with MGMT protein expression in human GIT carcinomas.
|
28135856 |
2017 |
|
Carcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
MGMT promoter hypermethylation and reduced expression has been found in some primary human carcinomas.
|
25579142 |
2014 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
SAC show higher frequency of MGMT loss compared to CC (50.6% vs. 25.3%; p = 0.001) especially in distal colon/rectum (60.0% vs. 21.6%; p = 0.0009).
|
22287190 |
2012 |
|
Carcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
In 34 cases where MSP results were available, MGMT promoter hypermethylation was detected in five cases (14.7%) with mucinous or clear cell carcinomas, but not in any of other histological types (P = 0.031).
|
21450028 |
2011 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Low immunohistochemical MGMT expression was noted in 50% of carcinomas.
|
21311951 |
2011 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The aim of this study was to investigate the methylation status of MutL homolog 1 (hMLH1), MutS homolog 2 (hMSH2), and O-6-methylguanine-DNA methyltransferase (MGMT) in a series of colorectal carcinomas that contain both adenomas and carcinomas.
|
21706233 |
2011 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We determined microsatellite instability (MSI), CIM, and expression of MLH1 and MGMT in 3 CD-associated small bowel carcinomas and corresponding non-neoplastic mucosa.
|
21042749 |
2010 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The objective of the study was to describe the antitumoral efficacy and toxicity of temozolomide in patients with aggressive pituitary tumors or carcinomas and evaluate the possible prognostic value of MGMT promoter methylation and protein expression.
|
20660056 |
2010 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Since some advanced carcinomas showed low MGMT activity, chemotherapy with O(6)-alkylating agents might be an alternative option.
|
20682983 |
2010 |
|
Carcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
MGMT was more frequently methylated in advanced gastric carcinomas.
|
20044616 |
2009 |
|
Carcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
K-ras mutations were evident in 6 ACF (23%) and in 3 carcinomas (33.3%), mostly associated with MGMT promoter hypermethylation.
|
17487400 |
2007 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Utilizing real-time PCR (MethyLight), we quantified DNA methylation in five CIMP-specific gene promoters [CACNA1G (calcium channel, voltage-dependent, T type alpha-1G subunit), CDKN2A (p16/INK4A), CRABP1 (cellular retinoic acid binding protein-1), MLH1 and NEUROG1 (neurogenin 1)] and MGMT in six synchronous carcinoma pairs (12 carcinomas) and eight synchronous carcinoma and adenoma pairs (16 tumors).
|
16699497 |
2006 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
MGMT+/hMLH1+ status was revealed in 2 gallbladder carcinoma cells, MGMT-/hMLH1+ in another 3 gallbladder carcinomas and MGMT-/hMLH1- in SW48.
|
16309194 |
2006 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Methylation of the MGMT promoter, associated with reduced MGMT expression, is found in nearly half of mouse skin tumors, but varies with both the tumor initiator and tumor promoter, and may be a key step in the progression from papillomas to carcinomas.
|
16094607 |
2006 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Loss of MGMT expression was found in 22.2% (6 of 27) of adenomas and 45.2% (28 of 62) of carcinomas.
|
15800999 |
2005 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
RARbeta, p16, and MGMT genes showed the highest incidences of methylation in premalignant and invasive carcinomas.
|
15173091 |
2004 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
BRAF/K-ras mutation, microsatellite instability, and promoter hypermethylation of hMLH1/MGMT in human gastric carcinomas.
|
15616773 |
2004 |
|
Carcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Its combination with hypermethylated in cancer 1 (HIC1), death-associated protein kinase (DAPK) and O-6-methylguanine DNA methyltransferase (MGMT), allowed the detection of aberrant methylation in 98% of colorectal carcinomas and 100% of gastric carcinomas.
|
15068392 |
2003 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, inactivation of different gene promoters by hypermethylation is significantly associated with microsatellite instability (MSI-H) and diploidy: hMLH1 determines MSI-H and MGMT the diploid status of gastric carcinomas.
|
12763209 |
2003 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We examined 39 surgically resected gallbladder carcinomas and 35 extrahepatic bile duct carcinomas and evaluated the expression of MGMT and MMR protein (hMLH1 and hMSH2) by immunohistochemical staining.
|
11986189 |
2002 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Hypermethylation of O(6)-MGMT with concurrent p53 and ras gene mutations were found in 6% and 13% of specimens, respectively; among those tumors with high Gleason scores were 2 carcinomas showing hypermethylated O(6)-MGMT with G-to-A transitions in K-ras.
|
12149142 |
2002 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
To examine correlation between the O6-methylguanine-DNA methyltransferase expression and the clinical data, we investigated O6-methylguanine-DNA methyltransferase expression in 315 consecutive gastric carcinomas.
|
12085181 |
2002 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In total, promoter hypermethylation of the MGMT gene was found in 8 (31%) of the 26 gastric carcinomas with reduced expression of MGMT protein, whereas the hypermethylation was not detected in the 18 carcinomas with non-reduced MGMT expression.
|
11519041 |
2001 |